Skip to main content
Premium Trial:

Request an Annual Quote

Joseph Hogan, John Dineen, Jim Doyle, James Dahlberg, Katherine Napier, Gordon Brunner, David Thompson, Glenn Muir, Robert Cascella, Mark Casey, Stuart Kingsley, Howard Doran

Premium
GE Healthcare CEO Joseph Hogan has left the company to take a position as CEO of the power and automation company ABB. GE has named John Dineen, who until now was CEO of GE Transportation, to fill Hogan’s spot.
 

 
Wisconsin Governor Jim Doyle has named Third Wave Technologies co-founder and University of Wisconsin professor James Dahlberg to be his science adviser, a newly created and unpaid position. Dahlberg has been at the university since 1969.
 

 
Third Wave is undergoing some executive shuffling of its board of directors as part of its merger agreement with Hologic.
 
Katherine Napier, Gordon Brunner, and David Thompson have resigned from Third Wave’s board. Glenn Muir, Robert Cascella, Mark Casey, Stuart Kingsley, and Howard Doran have been named director designees, but the company said it does not expect to name any of the director designees to any committee of the board at the present time.

Filed under

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.